

News Release

Lonza's New CCH® Endurance Feeder Offers Superior Protection with Low Maintenance

- NSF-Certified Feeder's Tablets Provide 3-in-1 Protection

Basel, Switzerland, 19 April 2018 –Lonza Water Care, a global leader in swimming pool treatment products and feeder systems, announced today the launch of a new offering: CCH® Endurance Feeder for use in pools and spas at hotels, motels, apartment and condominium complexes and other private and public venues.

Certified to NSF/ANSI Standard 50, this innovative system uses Lonza's slow-dissolving calcium hypochlorite tablets, which offers the convenience of traditional trichlor feeder systems with all the benefits of a non-stabilized calcium hypochlorite system.

With the simplicity of an erosion feeder, the streamlined CCH® Endurance Feeder is easy to install and service and requires minimal operator maintenance. Constructed with an easy-to-load cartridge to control dosing and a drain port to help prevent spills, the CCH® Endurance Feeder is the go-to-low-maintenance option.

The calcium hypochlorite tablets provide long-lasting action and pack a powerful 3-in-1 punch by killing harmful bacteria and pathogens that may cause recreational water illnesses, increasing calcium to help protect plaster pool surfaces and increasing alkalinity to help stabilize pH. Compared with liquid bleach, these tablets are highly concentrated, which reduces shipping and handling costs. As Class 2 oxidizers, these tablets work with oxidation-reduction potential (ORP) sensors and will not cause reduction of ORP.

CCH® Endurance calcium hypochlorite tablets chlorinate pool water without adding unnecessary cyanuric acid, which may reduce the effectiveness of chlorine, affect water balance and damage pool plaster.

More information is available online on the CCH® Endurance website <http://www.cchendurance.com/>.

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment.

Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com

Lonza Contact Information

Dominik Werner, Head Corporate Communications
Lonza Group Ltd
Tel +41 61 316 8798
dominik.werner@lonza.com

Constance Ward, Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.